E. Ohman J or Asset Management AB Grows Stock Holdings in Edwards Lifesciences Co. (NYSE:EW)

E. Ohman J or Asset Management AB grew its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 10.5% during the 4th quarter, HoldingsChannel reports. The fund owned 27,355 shares of the medical research company’s stock after buying an additional 2,600 shares during the period. E. Ohman J or Asset Management AB’s holdings in Edwards Lifesciences were worth $2,025,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently made changes to their positions in the company. FSA Wealth Management LLC purchased a new stake in Edwards Lifesciences during the 3rd quarter worth about $30,000. Prospera Private Wealth LLC bought a new stake in shares of Edwards Lifesciences during the third quarter valued at about $32,000. Avior Wealth Management LLC lifted its holdings in shares of Edwards Lifesciences by 138.7% in the third quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock worth $35,000 after buying an additional 308 shares in the last quarter. Roble Belko & Company Inc bought a new position in shares of Edwards Lifesciences in the fourth quarter valued at approximately $46,000. Finally, JFS Wealth Advisors LLC grew its stake in Edwards Lifesciences by 31.1% during the third quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company’s stock valued at $46,000 after acquiring an additional 166 shares in the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Stock Performance

NYSE:EW opened at $71.33 on Wednesday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. Edwards Lifesciences Co. has a fifty-two week low of $58.93 and a fifty-two week high of $96.12. The firm has a market cap of $42.07 billion, a PE ratio of 10.29, a price-to-earnings-growth ratio of 3.72 and a beta of 1.11. The business has a 50 day moving average price of $72.49 and a 200-day moving average price of $69.63.

Insider Activity at Edwards Lifesciences

In other news, VP Daniel J. Lippis sold 2,500 shares of the business’s stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $74.08, for a total transaction of $185,200.00. Following the transaction, the vice president now directly owns 23,189 shares of the company’s stock, valued at approximately $1,717,841.12. The trade was a 9.73 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the firm’s stock in a transaction on Wednesday, November 13th. The stock was sold at an average price of $65.57, for a total value of $327,850.00. Following the completion of the sale, the vice president now directly owns 46,936 shares of the company’s stock, valued at $3,077,593.52. The trade was a 9.63 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 8,000 shares of company stock worth $547,430 in the last three months. 1.27% of the stock is owned by insiders.

Analysts Set New Price Targets

Several research analysts have commented on the stock. Canaccord Genuity Group raised their price target on shares of Edwards Lifesciences from $63.00 to $68.00 and gave the company a “hold” rating in a report on Thursday, December 5th. Stifel Nicolaus raised Edwards Lifesciences from a “hold” rating to a “buy” rating and lifted their price objective for the company from $75.00 to $90.00 in a research note on Thursday, January 30th. Morgan Stanley restated an “equal weight” rating and issued a $70.00 target price on shares of Edwards Lifesciences in a research note on Friday, October 11th. JPMorgan Chase & Co. lifted their price target on Edwards Lifesciences from $72.00 to $78.00 and gave the company a “neutral” rating in a research report on Friday, October 25th. Finally, Daiwa America cut shares of Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 30th. One analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have given a buy rating to the company’s stock. According to data from MarketBeat.com, Edwards Lifesciences has an average rating of “Hold” and a consensus target price of $79.19.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.